Petrelintide is a long-acting amylin analogue being developed for chronic weight management. Its chemistry addresses two practical difficulties with amylin-based medicines: extending exposure after administration and preventing the peptide from becoming unstable or aggregating in a formulation. Human studies have now progressed from early pharmacokinetic trials to a published phase 2 obesity trial, with a separate diabetes trial reported in October 2026. Together, these studies support further development while showing why the weight response, formulation design and gastrointestinal tolerability need to be interpreted together.
Overview
Petrelintide was developed as ZP8396 and also appears as RO7895515 in Roche's development program. Zealand Pharma and Roche are developing it as a single agent and in a combination strategy. Fischer Munch and colleagues (2025) identify the selected candidate as peptide 40 and describe an amylin-derived molecule engineered for stability around neutral pH.
Molecular profile
- Development aliases
- ZP8396; RO7895515 Source
- Molecular form
- Acylated human-amylin analogue; selected development candidate peptide 40 Source
- Reported mass
- Approximately 4.2 kDa in the clinical report Source
- Stabilizing features
- Backbone N-methylation and a lactam bridge Source
- Exposure-extending feature
- C20 fatty-diacid modification Source
- Reported receptor activity
- AMY1, AMY3 and calcitonin receptors Source
- Clinical status
- Investigational; phase 3 program initiated Source
Forms and derivatives
ZP8396 / RO7895515
Development aliases identifying petrelintide within the Zealand and Roche programs.
Petrelintide plus enicepatide
Registered combination strategy that adds enicepatide's GLP-1/GIP receptor activity; its component-controlled design includes each candidate alone.
Its design includes a fatty-diacid modification to extend exposure, backbone N-methylation to reduce fibril formation, and a lactam bridge in place of the native disulfide bridge. A lactam is a cyclic amide linkage. These are changes to one defined candidate; ZP8396 and RO7895515 are development aliases for that candidate.
Uses and research areas
The clinical program examines weight management in adults with obesity or overweight and related conditions, both with and without type 2 diabetes. Researchers measure body weight alongside waist circumference, glycemic markers, lipids, tolerability and continuation of treatment. Each measurement adds a different part of the result: lower weight shows the overall response, while glycemic and lipid changes characterize associated metabolic effects.
In ZUPREME-1, Garvey and colleagues (2026) tested petrelintide against placebo without type 2 diabetes. The separate ZUPREME-2 trial examined people who also had diabetes, and Zealand reported its topline results on October 7, 2026. The sponsor has announced that a phase 3 monotherapy program has begun. A ClinicalTrials.gov record (2026) documents a combination study with enicepatide that addresses a further question: whether adding GLP-1/GIP receptor activity improves outcomes beyond either component alone.
Mechanism of action
Amylin signaling and appetite
Amylin is released by pancreatic beta cells alongside insulin after nutrient intake. Its receptor systems contribute to the signals that influence eating and post-meal metabolism. An amylin receptor consists of a calcitonin receptor associated with a receptor activity-modifying protein, or RAMP. The cell experiments by Christopoulos and colleagues (1999) established that this association changes hormone recognition and produces distinct receptor phenotypes.
Petrelintide has activity at AMY1, AMY3 and calcitonin receptors in the reported characterization. That receptor-family activity explains its classification and distinguishes its pharmacology from a GLP-1 receptor agonist. Within the body, receptor activation must be translated into changes in neural signaling and behavior; the receptor assay itself measures the cellular response to the compound.
Why chemical stability is part of the mechanism of development
Native human amylin can assemble into ordered aggregates called fibrils. For a therapeutic formulation, aggregation can change how much soluble material is available and complicate manufacturing and storage. Backbone N-methylation changes the peptide's capacity to make some of the hydrogen bonds involved in those ordered assemblies. The discovery program also altered degradation-prone residues and replaced the sulfur bridge with a more stable amide bridge. These changes addressed physical aggregation and chemical degradation as separate problems.
Fischer Munch and colleagues tested the resulting candidates in receptor assays, stability experiments and animal models. Their selected molecule retained activity while showing improved formulation properties. Neutral-pH compatibility also provides a rationale for combining petrelintide with another peptide in a finished formulation, where the two components must remain stable together. Clinical combination trials then determine the behavior of the combined treatment in people.
Pharmacokinetics
The phase 1 report by Brændholt Olsen and colleagues (2026) describes slow absorption after subcutaneous administration, with median peak times of 28–108 hours. Mean terminal half-life ranged from 213 to 257 hours in those cohorts. An intravenous cohort had a reported mean half-life of 239 hours, and comparison of the two routes yielded 77.4% absolute bioavailability for the studied 0.35-mg subcutaneous preparation.
Brændholt Olsen and colleagues measured petrelintide in six otherwise healthy men after a single 0.35-mg injection into a vein. The mean terminal half-life was 239 hours, describing how long the blood concentration took to fall by half during the final elimination phase. This intravenous estimate does not describe absorption after an injection under the skin.
Albumin association contributes to prolonged exposure by keeping the fatty-acid-modified peptide reversibly associated with a much larger circulating protein. The human measurements provide the practical evidence of persistence, while repeated-dose studies characterize the exposure reached during continuing treatment. Absorption, persistence and bioavailability answer related questions, but each needs its own measurement.
Research findings
Progression from phase 1 to ZUPREME-1
The initial studies assessed safety and exposure before undertaking a longer obesity study. ZUPREME-1 subsequently randomized 493 adults, of whom 485 received treatment, to petrelintide or placebo for 42 weeks, with dietary and physical-activity support. Its primary weight endpoint was assessed at week 28, an important detail when comparing it with later reports of the week-42 result.
In Garvey and colleagues' phase 2 report (2026), mean weight change at the primary endpoint ranged from −7.9% to −9.8% across active groups, compared with −1.7% with placebo, using the efficacy estimand. Weight continued to decline through week 42. The pattern did not imply that every increase in treatment amount produced additional benefit, which makes the joint assessment of efficacy and tolerability useful for selecting later trial regimens.
Zealand Pharma's report of the week-42 findings (September 2026) gave maximum mean reductions of 10.7% using the efficacy estimand and 10.2% using the treatment-policy estimand. The corresponding placebo values were 1.7% and 1.4%. The second approach addresses outcomes regardless of treatment discontinuation; the first addresses an on-treatment efficacy question. Their proximity in this trial is useful context, although the estimates still represent different questions.
ZUPREME-2 in type 2 diabetes
In its topline announcement (October 7, 2026), Zealand Pharma reported results in 220 people with overweight or obesity and type 2 diabetes. At week 28, maximum mean weight reduction using the efficacy estimand was 9.2%, compared with 2.0% for placebo. Maximum HbA1c reduction was 0.65 percentage points, compared with a 0.23-point increase with placebo.
These are sponsor-reported findings from a separate population. They extend the clinical program into diabetes and supply both weight and glycemic outcomes. The complete report will be needed to examine every group, missing-data analysis and safety event in the same detail as the published obesity trial.
Safety and tolerability
Petrelintide remains investigational and is not FDA-approved as of October 13, 2026. In ZUPREME-1, nausea occurred in 20% of petrelintide-treated participants and 6% of placebo participants, and was predominantly mild during escalation. Vomiting occurred in 3% and 6%, respectively; reported diarrhea rates were similar. This gives a more precise picture of tolerability than a broad statement that gastrointestinal effects matched placebo.
Zealand reported discontinuation because of gastrointestinal events in 1.9% of petrelintide recipients and 1.7% of placebo recipients in ZUPREME-2. Those figures concern the diabetes trial and that specific reason for discontinuation. Larger phase 3 studies will examine continued treatment, less common events and broader clinical outcomes.
The available studies do not establish safety in pregnancy, childhood or every combination with other metabolic medicines. Commercial material bearing the development name has not been shown to reproduce the manufacturing, exposure or results of the trial preparation.
What the research means
Petrelintide's program joins a formulation achievement to a clinical result. The chemistry made a long-acting amylin-derived candidate suitable for testing, and controlled studies showed weight reduction with a defined gastrointestinal event profile. The phase 2 results also suggest that the response may approach a useful level before the largest tested amount, an observation that later trials can use when balancing benefit and tolerability.
Future studies need to establish whether these findings translate into durable treatment in larger populations, improvements in complications of obesity, and an effective combination with enicepatide. Formulation compatibility makes a combination feasible to investigate; the component-controlled study is what can show whether the combination adds benefit and how it changes adverse effects.
FAQs
Are ZP8396 and RO7895515 different peptides?
They are development aliases for petrelintide. The ClinicalTrials.gov combination record (2026) lists both under the same intervention, allowing older and newer program records to be connected.
Why do ZUPREME-1 summaries use both 28 and 42 weeks?
The trial's primary weight endpoint was at week 28 and treatment continued to week 42. Garvey and colleagues (2026) report the primary result and continued later weight reduction. Both time points belong to the study but answer different follow-up questions.
Does neutral-pH stability establish a clinical advantage?
Stability helps a formulation retain the intended material and permits combinations to be investigated. Fischer Munch and colleagues (2025) tested those chemical properties; clinical benefit and tolerability are evaluated separately in human trials.
Has petrelintide been shown to preserve muscle in people?
Body weight and waist circumference cannot by themselves distinguish fat change from muscle change. A clinical claim about muscle preservation requires direct body-composition and functional measurements in people. The obesity outcomes presented here concern the measurements reported in the cited trials.
Is petrelintide an approved weight-management medicine?
It remains investigational as of October 13, 2026. Zealand Pharma's October 2026 announcement reports the initiation of phase 3 studies after phase 2 findings.
Comparisons and related reading
Eloralintide and cagrilintide provide other examples of sustained amylin-family pharmacology. Zenagamtide, also called amycretin, joins GLP-1 and amylin-family activity in one peptide. These comparisons are most useful for understanding chemical design and the questions tested in each trial; percentages from different studies depend on population, follow-up and estimand.
References
The development experiments explain how changes to aggregation-prone regions and the bridge produced candidate peptide 40.
The single- and repeated-dose trials characterize slow absorption, intravenous persistence and absolute subcutaneous bioavailability.
Distinguishes the week-28 primary endpoint from later weight changes and supplies the nausea, vomiting and diarrhea findings.
The sponsor reported weight loss at week 42 using two analyses that handle treatment stopping differently, after the trial’s primary assessment at week 28. The announcement also describes plans for phase 3.
The latest sponsor report extends the program to diabetes and reports weight, HbA1c and gastrointestinal-event discontinuation.
Verifies the component-controlled combination design and the development aliases for both candidates.
Coexpression experiments explain how calcitonin receptors acquire amylin-receptor pharmacology through RAMP association.
Glossary
- Fibrillation
- Assembly of peptide molecules into ordered, elongated aggregates.
- N-methylation
- Adding a methyl group to a backbone nitrogen, changing the peptide's bonding and conformational properties.
- Lactam bridge
- A cyclic amide linkage connecting parts of a molecule.
- Bioavailability
- The fraction of an administered amount reaching systemic circulation, assessed relative to an intravenous reference.
- Treatment-policy estimand
- A treatment-effect question that includes outcomes regardless of treatment discontinuation.
- HbA1c
- Glycated hemoglobin, a marker of preceding average glycemic exposure.